Allarity Therapeutics, Inc. entered into a Fourth Amendment to the Exclusive License Agreement with Eisai, Inc. to postpone the extension payment and restructure the payment schedule for the Stenoparib drug; The Company and 3i entered into an Amendment to Modification and Exchange Agreement to correct an error in the Original Agreement regarding the exchange of shares.